DiabetologyNews.net

Diabetology Xagena

Xagena Mappa
Medical Meeting
Gastrobase.it
Reumabase.it

The aim was to assess the efficacy and safety of Dapagliflozin ( Forxiga ) as add-on therapy in patients with type 2 diabetes who were inadequately controlled with a dipeptidyl peptidase-4 inhibitor w ...


Metformin ( Glucophage ) is the only first-line oral hypoglycaemic drug for type 2 diabetes recommended by international guidelines with proven efficacy, safety, and cost-effectiveness. However, littl ...


According to research published in Diabetologia, the journal of the European Association for the Study of Diabetes, people who have diabetes at the time they are diagnosed with cancer are more likely ...


New research published in Diabetologia, the journal of the European Association for the Study of Diabetes ( EASD ), has shown that diabetes mellitus in women is associated with an increased risk of st ...


Clinical trials have demonstrated that Metformin increases the efficiency of systemic therapy in cancer patients. Researchers examined whether the efficacy of conventional treatment of differentiat ...


The aim of the study was to investigate the long-term safety and efficacy of Empagliflozin ( Jardiance ), a sodium glucose cotransporter 2 inhibitor ( SGLT2 ); Sitagliptin ( Januvia ); and Metformin ( ...


Glucagon-like peptide-1 receptor agonists Exenatide ( Byetta ) and Liraglutide ( Victoza ) have been shown to improve glycaemic control and reduce bodyweight in patients with type 2 diabetes.The effic ...


The cardiovascular safety and efficacy of many current antihyperglycemic agents, including Saxagliptin ( Onglyza ), a dipeptidyl peptidase 4 ( DPP-4 ) inhibitor, are unclear.Researchers have randomly ...


Researchers at the National Institutes of Health have clarified in rodent and test tube experiments the role that inflammation plays in type 2 diabetes, and revealed a possible molecular target for tr ...


Diabetes is a risk factor for dementia. It is unknown whether higher glucose levels increase the risk of dementia in people without diabetes mellitus.Researchers used 35,264 clinical measurements of g ...


Guidelines suggest setting individualised targets for glycaemic control in elderly patients with type 2 diabetes, despite no evidence.The aim of the study ( INTERVAL ) was to assess the feasibility of ...


Studies have shown that, when implemented early in the course of type 2 diabetes mellitus, treatment with intensive Insulin therapy for 2-3 weeks can induce a glycaemic remission, wherein patients are ...


Effective reduction of albuminuria and blood pressure in patients with type 2 diabetes mellitus who have nephropathy is seldom achieved with available treatments. Researchers tested the effects of tre ...


The FDA ( Food and Drug Administration ) has approved Invokana ( Canagliflozin ) for the treatment of adults with type 2 diabetes. Invokana is the first in a new class of medications called sodium glu ...


The European Medicines Agency ( EMA ) has completed a review of new data on the cancer risk with Insulin glargine-containing medicines. The Agency’s Committee for Medicinal Products for Human Use ( CH ...